News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Withdraws Bid For EU Regulatory OK Of Asthma Medicine
November 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Merck & Co. (MRK) has withdrawn its application for European regulatory approval of an asthma treatment, citing outstanding questions by regulators.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
Government
Rare Pediatric Disease Vouchers, PBM Reform, up for Vote in House
January 21, 2026
·
2 min read
·
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
Manufacturing
CDMOs Pin Hopes for Accelerating Uptake at New US Sites on FDA’s PreCheck Program
January 20, 2026
·
4 min read
·
Nick Paul Taylor
FDA
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year
January 19, 2026
·
6 min read
·
Heather McKenzie
